Introduction: The Promise of Graphene in Biomedicine

Graphene-based nanostructures have quickly moved from fundamental materials science into the forefront of biomedical engineering, particularly in the fight against cancer. Their remarkable combination of physical, chemical, and biological properties—ultrahigh surface area, exceptional mechanical strength, tunable surface chemistry, and superior electrical and thermal conductivity—positions them as versatile platforms for therapeutic delivery, imaging, and diagnostics. Unlike many conventional nanoparticles, graphene derivatives can be engineered at the atomic level to carry multiple payloads, recognize specific cellular markers, and respond to external stimuli. This capacity for multifunctionality makes them especially attractive for targeted cancer therapy, where precision and minimal off-target effects are paramount.

In this article we explore how graphene-based nanostructures are being designed and applied in cancer treatment and medical research. We examine their fundamental properties, the mechanisms behind targeted drug delivery, photothermal and photodynamic therapies, their roles in advanced imaging and biosensing, and the critical challenges that must be addressed before they can become standard clinical tools.

What Are Graphene-Based Nanostructures?

Graphene is a single atom-thick sheet of carbon atoms arranged in a two-dimensional honeycomb lattice. When isolated from graphite, it exhibits extraordinary properties: a specific surface area of ~2630 m²/g (the highest of any known material), high electron mobility, and excellent mechanical stiffness. However, pristine graphene is hydrophobic and chemically inert, limiting direct biological applications. To overcome this, researchers have developed several graphene derivatives that are more processable and functionalizable.

Graphene Oxide (GO)

Graphene oxide is produced by oxidizing graphite, introducing hydroxyl, epoxide, carbonyl, and carboxyl groups onto the basal planes and edges. This process renders the material hydrophilic and dispersible in water, paving the way for biological interactions. The abundant oxygen-containing groups also serve as anchoring points for covalent conjugation of drugs, targeting ligands, imaging agents, and polymers. GO sheets typically range from a few hundred nanometers to several micrometers in lateral size, with thickness of about 1 nm.

Reduced Graphene Oxide (rGO)

Partial reduction of GO—through chemical, thermal, or electrochemical methods—removes many oxygen groups and restores some of the pristine graphene’s electrical conductivity and light absorption properties. rGO retains a degree of functional groups for further modification while exhibiting stronger absorption in the near-infrared (NIR) region, making it particularly useful for photothermal therapy.

Graphene Quantum Dots (GQDs)

GQDs are small fragments of graphene (typically <10 nm) that exhibit quantum confinement effects and fluorescence. Their tunable photoluminescence, low toxicity, and small size allow them to function as both imaging probes and drug carriers. Unlike larger graphene sheets, GQDs can cross biological barriers more efficiently and are cleared renally, potentially reducing long-term accumulation concerns.

Synthesis and Functionalization Strategies

Common synthesis routes include the Hummers’ method for GO production, followed by exfoliation and reduction. For GQDs, top-down approaches (e.g., hydrothermal cutting of GO) and bottom-up methods (e.g., carbonization of small molecules) are used. Surface engineering is critical: polyethylene glycol (PEG) coatings improve colloidal stability and reduce protein corona effects; targeting moieties such as folic acid, transferrin, or antibodies against EGFR are attached via amide bonds or click chemistry; and pH-responsive linkers enable drug release in the acidic tumor microenvironment.

Applications in Targeted Cancer Therapy

The core advantage of graphene nanostructures in oncology is their ability to concentrate therapeutic agents at the tumor site while sparing healthy tissues. Two main targeting strategies are employed: passive targeting via the enhanced permeability and retention (EPR) effect, where nanosized particles accumulate in leaky tumor vasculature, and active targeting using molecular recognition.

Drug Delivery Systems

Graphene oxide’s large surface area can adsorb high loadings of aromatic anticancer drugs such as doxorubicin (DOX), paclitaxel, and camptothecin through π–π stacking interactions. Loading capacities can exceed 200% w/w—far higher than conventional liposomes or polymer nanoparticles. Once at the tumor, drug release can be triggered by changes in pH (lower in lysosomes and tumor interstitium), glutathione concentration (higher in cancer cells), or external stimuli such as NIR light. For example, a study by Yang et al. (2011) demonstrated that GO functionalized with PEG and loaded with DOX exhibited pH-responsive release and significantly enhanced cytotoxicity against breast cancer cells compared to free DOX.

Dual-drug delivery is also achievable: one drug loaded via π–π stacking, another covalently conjugated, allowing synergistic effects. Researchers have developed GO-based carriers that co-deliver DOX and an siRNA targeting anti-apoptotic proteins, thereby overcoming drug resistance in ovarian cancer models.

Photothermal and Photodynamic Therapy

Graphene derivatives, particularly rGO, absorb strongly in the NIR region (700–900 nm), where biological tissues are relatively transparent. When exposed to NIR laser irradiation, the nanostructures convert light into heat, raising local temperatures above 42°C and inducing apoptosis or necrosis in cancer cells. This photothermal therapy (PTT) can be performed with high spatial precision. Combining PTT with chemotherapy (chemo-photothermal therapy) yields synergistic effects—heat enhances cell membrane permeability, increasing drug uptake, while the drug sensitizes cells to thermal damage.

Photodynamic therapy (PDT) can also be integrated by attaching photosensitizers (e.g., chlorin e6, methylene blue) to the graphene surface. Upon light activation, the photosensitizer generates reactive oxygen species (ROS) that kill cancer cells. Graphene acts both as a carrier and as a fluorescence quencher, reducing off-target activation until the photosensitizer is released or comes into proximity with target cells.

In vivo studies in mouse xenograft models have shown that a single dose of PEGylated rGO followed by NIR irradiation can completely eradicate tumors without significant systemic toxicity (Robinson et al., 2011). Such results have propelled graphene-based PTT toward early-phase clinical exploration.

Combination Therapy and Theranostic Platforms

The ultimate goal in nanomedicine is theranostics—integrating therapy and diagnostics within a single platform. Graphene nanostructures are ideal theranostic agents because they can simultaneously carry therapeutic drugs, imaging probes, and targeting ligands. For instance, gadolinium-loaded GO or iron oxide–graphene hybrids enable MRI-guided PTT. Similarly, radiolabeled graphene (e.g., with ¹²⁵I or ⁶⁴Cu) allows positron emission tomography (PET) tracking of biodistribution and tumor accumulation.

Recent advances include the development of “all-in-one” nanoplatforms where a single graphene sheet is decorated with a chemotherapeutic prodrug, a NIR-photosensitizer, a folic acid targeting ligand, and a near-infrared fluorescent dye for image-guided therapy. Such constructs have demonstrated enhanced therapeutic efficacy and real-time monitoring in animal models of colorectal cancer and glioblastoma.

Role in Medical Research Beyond Therapy

While cancer treatment is the most visible application, graphene nanostructures are also reshaping fundamental medical research, particularly in imaging, biosensing, and tissue engineering.

Imaging and Diagnostics

Graphene’s ability to quench fluorescence makes it a valuable component in “turn-on” biosensors. In the absence of a target analyte, a fluorescent probe attached to graphene is quenched; binding of the analyte releases the probe, restoring fluorescence. This principle has been used to detect DNA mutations, microRNA biomarkers, and proteins at picomolar concentrations. GO-based sensors have achieved detection limits as low as 10 aM for DNA targets, rivaling PCR-based methods.

For in vivo imaging, graphene can be functionalized with paramagnetic or superparamagnetic agents for MRI. For example, GO conjugated with Mn²⁺-based contrast agents provides T1-weighted contrast with high relaxivity. Additionally, the intrinsic fluorescence of GQDs in the blue-green range has been exploited for cellular imaging without the photobleaching typical of organic dyes.

Biosensors for Early Detection

Graphene-based field-effect transistors (FETs) can detect cancer biomarkers directly from blood or serum samples. The binding of a biomarker (e.g., PSA, CEA, HER2) to an antibody on the graphene channel alters its electrical conductivity, enabling label-free, real-time detection. These devices have shown sensitivity down to femtomolar concentrations, with response times on the order of minutes. Recent work has demonstrated a graphene FET array that simultaneously detects multiple biomarkers for pancreatic cancer, achieving 95% accuracy in distinguishing patient samples from healthy controls (Hao et al., 2020).

Regenerative Medicine and Tissue Engineering

Graphene’s mechanical properties support its use as a scaffold for bone, cartilage, and neural tissue regeneration. GO-coated polymers promote osteogenic differentiation of mesenchymal stem cells by concentrating growth factors and providing a stiff matrix. In neural research, conductive graphene substrates have been shown to enhance neurite outgrowth and synaptic activity, offering potential for spinal cord injury repair.

Future Perspectives and Challenges

Despite the remarkable progress, several hurdles must be cleared before graphene-based nanostructures can be routinely used in clinical settings.

Biocompatibility and Toxicity

The biological response to graphene depends heavily on its size, shape, surface chemistry, and dose. Small GQDs (<10 nm) are generally non-cytotoxic at moderate concentrations, while larger GO sheets can accumulate in lungs, liver, and spleen and induce inflammatory responses. Pristine graphene can cause oxidative stress in cells. Coating with PEG, dextran, or albumin significantly reduces toxicity, but long-term in vivo studies—especially concerning chronic inflammation, fibrosis, and potential genotoxicity—are still scarce. Standardized toxicity assays based on OECD guidelines are urgently needed.

Scalability and Reproducibility

Current synthesis methods, such as Hummers’ oxidation, produce GO with batch-to-batch variations in sheet size, oxygen content, and defect density. This lack of reproducibility hampers clinical translation. Advances in controlled exfoliation and purification, as well as defined quality control metrics (e.g., C/O ratio, Raman D/G ratio), are being developed. Industrial-scale production of medical-grade graphene nanomaterials remains a challenge but is being tackled by companies like XG Sciences and Graphenea.

Biodistribution and Clearance

Large graphene sheets (>100 nm) are primarily taken up by the reticuloendothelial system and can persist in organs for months. Smaller GQDs and ultrathin monolayer GO (<20 nm) are cleared through renal filtration, but their circulation time is short, limiting tumor accumulation. Strategies to optimize size and surface modification for the ideal balance of circulation, accumulation, and clearance are under active investigation.

Clinical Trials and Regulatory Pathways

As of 2025, only a handful of graphene-based medical products have entered early clinical trials, mostly for wound healing and drug delivery. No graphene nanostructure has yet received FDA approval for cancer therapy. Regulatory agencies require extensive evidence of safety, efficacy, and manufacturing consistency. The European Commission’s Graphene Flagship program has dedicated a work package to translating graphene into clinical applications, and collaborations between academia and industry are accelerating the process. One promising avenue is the use of graphene-based photothermal agents in combination with already-approved chemotherapeutics, which may follow a 510(k) pathway rather than a full de novo review.

Outlook

Graphene-based nanostructures represent a paradigm shift in how we approach cancer therapy and medical research. Their ability to combine high drug loading, specific targeting, photothermal/photodynamic action, and diagnostic imaging in a single platform offers a level of multifunctionality that few other materials can achieve. As the challenges of toxicity, manufacturing, and regulation are systematically addressed, we can expect to see graphene-based nanotherapeutics entering clinical practice within the next decade. For researchers, the field remains rich with opportunity—from designing smart responsive coatings to integrating machine learning for optimizing nanosheet properties. The journey from bench to bedside is long, but the promise of graphene is too compelling to ignore.